Skip to content
Menu

Reported Sunday, Viking Therapeutics Reports 74% Of Subcutaneous VK2735 Participants Improved BMI Category Versus 15% On Placebo After 13 Weeks, With Improved Cardiometabolic Markers

Benzinga Newsdesk 2 days ago

News

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

VENTURE Analysis Finds 74% of Participants Receiving Subcutaneous VK2735 Improved by at Least One BMI Category after 13 WeeksVK2735 Treatment Led to Improvement Across Multiple Cardiometabolic Markers

VENTURE Analysis Finds 74% of Participants Receiving Subcutaneous VK2735 Improved by at Least One BMI Category after 13 Weeks

VK2735 Treatment Led to Improvement Across Multiple Cardiometabolic Markers

Read at benzinga.com